PhRMa R&D Costs Are Much Lower Than Claimed
The deeper problem is that current incentives reward drug companies to develop mainly new, but not better medicines at ever higher prices.
The deeper problem is that current incentives reward drug companies to develop mainly new, but not better medicines at ever higher prices.
Why did the BMJ fail to disclose its partnership agreement with Merck, major vaccine manufacturer–13 vaccines, including the controversial MMR vaccine ?
Vaccines are legally classified as "unavoidably unsafe"–an indication that they pose an inherent risk. Vaccines have not been subjected to scientifically rigorous placebo controlled safety trials before they have been approved for use in children. The public debate over vaccine safety has intensified as a continuing stream of news reports…
TAKE ACTION! Help rescind proposed firing of FDA scientist
From 1991-2000 qui tam law suits accounted for only 9% of settlements with the government. But from 2001-2010, qui tam settlements comprised 67% of the billions in payouts
In 2008, 6,485 trials were conducted off shore with almost no FDA oversight. Seventy-eight percent of all human test subjects were enrolled at foreign sites.
“To ghostwrite an entire textbook is a new level of chutzpah,” said Dr. David A. Kessler, former commissioner of the Food and Drug Administration, after reviewing the documents. “I’ve never heard of that before. It takes your breath away.”
"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.”
"What’s gone on with the pharmaceutical industry is a physician arms race to buy off doctors…"
"The current way that DSMBs are constituted and report has resulted in a loss of faith." NEJM
The catalyst for Dr. Elliott’s article was the tragic case of Dan Markingson, a 26-year old who committed suicide in May 2004, while enrolled in the CAFE trial, prescribed Seroquel. This case encapsulates the tragic consequences of a broken system which is not designed to detect the hazards for human subjects posed by market-driven research.
"The study started out with 20 subjects…For about a week there were 14 subjects. Then they started dropping…Now, we’re down to 7."